 |
|
Weighing costs, benefits of HIV treatments
September 16, 2009HANOVER, NH - Prevention versus treatment? Cost versus efficacy? So go two of the dilemmas looming over Dartmouth's Paul E. Palumbo, M.D., and his fellow researchers in the race to fight HIV and other infectious diseases in the developing world - especially among women and their young children.
"We have this big quandary in resource-limited countries," says Palumbo, a Dartmouth Medical School professor of medicine and pediatrics. "We have a simple approach that is cost-effective, and reduces transmission [of HIV] by 50 percent. The Achilles heel of that approach is that in the mother and in any infant who does become infected, the virus learns to become drug-resistant."
Palumbo is co-leading a clinical study of anti-HIV medicines in Africa and India for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT). The randomized trial found that a cohort of 82 HIV-infected children ages 6 to 35 months responded better to treatment with the protease-inhibiting drug lopinavir (LPV/r) than did a cohort of 82 children in the same age group who received the anti-retroviral drug nevirapine (NVP). The infants all had previously received a single dose of NVP in liquid form at birth, and their mothers each had taken NVP in the form of a single pill during labor in an attempt to prevent HIV transmission.
In July, IMPAACT leaders presented their findings in South Africa at the inaugural International Workshop on HIV Pediatrics and the International AIDS Society's fifth Conference on HIV Pathogenesis Treatment and Prevention. Chief sponsors of the trial are the National Institute of Allergy and Infectious Diseases (NIAID) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Findings also revealed that the LPV/r arm of the trial showed results so much better that in the spring of 2009, an independent data and safety monitoring board (DSMB) halted the NVP arm and gave the go-ahead for IMPAACT to enroll children who did not receive NVP at birth.
"These findings," NIAID stated in a recent bulletin, "provide clear evidence in support of the current World Health Organization recommendation that HIV-infected infants who have received NVP at birth should be started on an LPV/r-based treatment regimen whenever possible."
But here's the rub: LPV/r is a relatively expensive drug more available in the developed than the developing world, and it must be kept cold - a challenge in sub-Saharan Africa and much of India. On the other hand, NVP is relatively cheap and accessible in developing nations.
Breast-feeding presents another challenge: While it can lead to infection of the infant of an HIV-positive mother, the mother's milk also protects the child against many common infections of infancy, Palumbo says. Also, formula feeding to prevent transmission of HIV - a common practice in the developed world - leaves infants prone to suffer from upper-respiratory infections, diarrhea, and other maladies. According to estimates of the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF), more than nine million children younger than 5 are expected to die each year - 17 percent from pneumonia, 17 percent from diarrhea, and 7 percent from malaria, as opposed to 1.5 percent from HIV/AIDS. At least 10 percent of enrollees in the IMPAACT study already are or may be suffering from tuberculosis.
That's why, as the trial continues, IMPAACT will examine whether NVP becomes effective again in HIV-positive children after a certain age.
"There's a big, dynamic struggle going on as we speak," Palumbo says. "We're right in the middle of this active debate. The question is, how fast can we do it? Can scientific mandates be translated into practice? - Those data are going to be used to inform the prevention and treatment guidelines at WHO. I still don't know how it's going to play out." Palumbo also serves as executive director of the Dartmouth-affiliated DarDar Pediatric Program in Tanzania.
Dartmouth College
In July, IMPAACT leaders presented their findings in South Africa at the inaugural International Workshop on HIV Pediatrics and the International AIDS Society's fifth Conference on HIV Pathogenesis Treatment and Prevention. Chief sponsors of the trial are the National Institute of Allergy and Infectious Diseases (NIAID) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Findings also revealed that the LPV/r arm of the trial showed results so much better that in the spring of 2009, an independent data and safety monitoring board (DSMB) halted the NVP arm and gave the go-ahead for IMPAACT to enroll children who did not receive NVP at birth.
"These findings," NIAID stated in a recent bulletin, "provide clear evidence in support of the current World Health Organization recommendation that HIV-infected infants who have received NVP at birth should be started on an LPV/r-based treatment regimen whenever possible."
But here's the rub: LPV/r is a relatively expensive drug more available in the developed than the developing world, and it must be kept cold - a challenge in sub-Saharan Africa and much of India. On the other hand, NVP is relatively cheap and accessible in developing nations.
Breast-feeding presents another challenge: While it can lead to infection of the infant of an HIV-positive mother, the mother's milk also protects the child against many common infections of infancy, Palumbo says. Also, formula feeding to prevent transmission of HIV - a common practice in the developed world - leaves infants prone to suffer from upper-respiratory infections, diarrhea, and other maladies. According to estimates of the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF), more than nine million children younger than 5 are expected to die each year - 17 percent from pneumonia, 17 percent from diarrhea, and 7 percent from malaria, as opposed to 1.5 percent from HIV/AIDS. At least 10 percent of enrollees in the IMPAACT study already are or may be suffering from tuberculosis.
That's why, as the trial continues, IMPAACT will examine whether NVP becomes effective again in HIV-positive children after a certain age.
"There's a big, dynamic struggle going on as we speak," Palumbo says. "We're right in the middle of this active debate. The question is, how fast can we do it? Can scientific mandates be translated into practice? - Those data are going to be used to inform the prevention and treatment guidelines at WHO. I still don't know how it's going to play out." Palumbo also serves as executive director of the Dartmouth-affiliated DarDar Pediatric Program in Tanzania.
Dartmouth College
Infectious Diseases Current Events and Infectious Diseases News RSSStudy details machinery of immune protection against inflammatory diseases like colitis
Scientists report a protein made by a gene already associated with a handful of human inflammatory immune diseases plays a pivotal role in protecting the intestinal tract from colitis.
Conventional infection control measures found effective in reducing MRSA rates
Scientists at The Virginia Commonwealth University Medical Center found that an emphasis on compliance with non-pathogen specific infection control practices such as hand hygiene, efforts to reduce device-related infections and chlorhexidine bathing (a daily bath with the same antibacterial agent used by surgeons to "scrub in" before an operation), is successful in reducing rates of healthcare-associated methicillin-resistant Staphylococcus aureus.
Stress during pregnancy may increase offspring's risk of asthma
Stress during pregnancy may raise the risk of asthma in offspring, according to researchers at Brigham and Women's Hospital and Harvard Medical School in Boston.
France's national program to reduce HAIs reports important successes; uses mandatory reporting
Researchers evaluating France's national infection control program for healthcare facilities found significant decreases in the rates of healthcare-associated infections (HAIs) since 2004.
ID Physicians Call for 10 New Antibiotics by 2020
As the deaths and suffering caused by antibiotic-resistant bacterial infections continue to rise around the world, the Infectious Diseases Society of America (IDSA) is urging a global commitment to develop 10 new antibiotics by 2020, known as the 10 x '20 initiative, to address this public health crisis and safeguard patients' health.
Preventive Behaviors Limited Household Transmission of H1N1 Influenza During Initial Outbreak
Simple, common sense behaviors, including having a discussion at home about how to prevent influenza, can help limit the spread of H1N1 in a household, according to a study of the initial outbreak in New York City in 2009.
Strategies increase health-care worker vaccination rates -- protecting patients
Healthcare personnel influenza immunization rates have remained low, despite recommendations from the Centers for Disease Control and Prevention (CDC) and other leading healthcare organizations that all healthcare personnel receive annual flu vaccines.
Research identifies potential new use for cancer treatment
Drugs increasingly used to treat cancer could have a major impact on a wide range of infectious diseases, according to new research.
Barrier in mosquito midgut protects invading pathogens
Scientists studying the Anopheles gambiae mosquito - the main vector of malaria - have found that when the mosquito takes a blood meal, that act triggers two enzymes to form a network of crisscrossing proteins around the ingested blood.
New approach to immune cell analysis seen as first step to better distinguish health and disease
Investigators have developed a new mathematical approach to analyze molecular data derived from complex mixtures of immune cells. This approach, when combined with well-established techniques, readily identifies changes in small samples of human whole blood, and has the potential to distinguish between health and disease states.
More Infectious Diseases Current Events and Infectious Diseases News Articles
 |
Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases: Expert Consult Premium Edition - Enhanced Online Features and Print (Two Volume Set) by Gerald L. Mandell (Author) After thirty years, PPID is still the reference of choice for comprehensive, global guidance on diagnosing and treating the most challenging infectious diseases. Drs. Mandell, Bennett, and Dolin have substantially revised and meticulously updated, this new edition to save you time and to ensure you have the latest clinical and scientific knowledge at your fingertips. With new chapters, expanded and updated coverage, increased worldwide perspectives, and many new contributors, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th Edition helps you identify and treat whatever infectious disease you see. And, as an Expert Consult title with enhanced online features, this updated 7th edition comes with convenient access to the full text online, regular updates... |
 |
Infectious Diseases: A Clinical Short Course, Second Edition (LANGE Clinical Medicine) by Frederick Southwick (Author) Gain a full understanding of clinical infectious diseases in just thirty days A Doody's Core Title! No other resource makes clinical infectious diseases more manageable and easy to master than Infectious Diseases: A Clinical Short Course. This one-of-a-kind self-instruction tool is organized by system/region as opposed to pathogens -- simulating how common pathogens and disorders would be encountered in rounds or in practice. For this reason, this remarkable resource is unsurpassed for learning how to associate pathogens with their corresponding impact on actual patients. Features: A true, concise “short course” format that can be read and understood in the span of a 30-day infectious disease rotation Numerous case examples... |
 |
Clinical Infectious Disease by David Schlossberg (Editor) This clinically-oriented, user-friendly text is the best on the market for infectious disease. Complete and comprehensive, Schlossberg's text will be an effective reference for any practitioner who may encounter these afflictions. The orientation of the volume is multi-faceted: in addition to the traditional organization of organ system and pathogen-related information, this text includes specific sections on the susceptible host, travel-related infections, nosocomial infections, infections related to trauma, and bioterrorism. The information on post-surgical infections will be of great interest to practicing surgeons. Informative algorithms, tables, and high-quality color photographs supplement many of the chapters in this conveniently-sized volume. For practicality and ease of use, one... |
 |
The A to Z of Infectious Diseases (Concise Encyclopedia) by Carol Turkington (Author), Bonnie Lee, M.d. Ashby (Author) In the past 25 years, more than 30 new germs affecting humans have emerged onto the medical scene, most of them rising from animals. New diseases like the avian flu, Ebola, SARS, and weaponized viruses such as anthrax and smallpox pose a growing danger to the world. With the threat of infectious diseases remaining constant, it is essential to have clear and concise information on this topic. "The A to Z of Infectious Diseases" provides more than 600 up-to-date entries covering the latest research, new treatments and vaccines, and rising diseases such as mad cow disease. Appendixes include drugs used to treat infectious diseases, tips for home disinfection, and lists of helpful organizations and publications, making this the ultimate resource for knowledge about infectious diseases. Topics... |
 |
Infectious Disease: Pathogenesis, Prevention and Case Studies by Nandini Shetty (Author), Julian W Tang (Author), Julie Andrews (Author) “… a fun and readable book that engages the imagination and retains the interest of the clinically oriented reader while conveying an understanding of the direct implications of molecular characteristics of infectious agents to the practice of medicine..” –Emerging Infectious Diseases, January 2010 “… provides a valuable overview of the basic principles and issues pertaining to the pathogenesis and prevention of infectious diseases. The illustrations, the chapter summaries with relevant information, and the case studies are all particularly useful for the targeted readers. The book is well designed and manages to convey the general concepts of the various aspects of infectious diseases without overwhelming the reader with too much information… recommended for... |
 |
Infectious Diseases, Second Edition (EXPERT GUIDE SERIES- AMERICAN COLLEGE OF PHYSICIANS) by James S. Tan (Editor), Michael J. Tan (Editor), Robert A. Salata (Editor), Thomas M. File Jr. (Editor) Here s the expert guidance practitioners need to diagnose and treat the most commonly encountered infections! This fully revised and updated New Edition keeps readers current with the latest etiologic agents, the most appropriate diagnostic tests, and the most effective management options. The 2nd Edition features new chapters on Antimicrobial Agents for the Primary Care Physician and Prosthetic Joint Infections. FEATURES: -Examines infections of the central nervous system, heart and blood vessels, gastrointestinal tract, genitourinary system, respiratory tract, skeletal system, and the skin. -Features individual chapters on HIV, herpes virus, Lyme disease, and malaria. -Puts key information at the reader s fingertips with diagnostic and treatment tables throughout the text. -Reviews... |
 |
Case Studies in Infectious Disease by Peter Lydyard (Author), Michael Cole (Author), John Holton (Author), Will Irving (Author), Nino Porakishvili (Author), Pradhib Venkatesan (Author), Kate Ward (Author) Case Studies in Infectious Disease presents forty case studies featuring the most important human infectious diseases worldwide. Written for students of microbiology and medicine this book describes the natural history of infection from point of entry of the pathogen through pathogenesis, followed by clinical presentation, diagnosis and treatment. Five core sets of questions are posed in each case. What is the nature of the infectious agent, how does it gain access to the body, what cells are infected, and how does the organism spread? What are the host defense mechanisms against the agent and how is the disease caused? What are the typical manifestations of the infection and the complications that can occur? How is the infection diagnosed and what is the... |
 |
Infectious Disease: A Scientific American Reader (Scientific American Readers) by Scientific American (Editor) The international public health scare that resulted last year when a man infected with multidrug-resistant tuberculosis flew overseas from the United States and back illustrates both the fear and the potential impact of highly infectious diseases in a global age. At a time when scientists warn of the potential for an influenza epidemic to rival the deadly outbreak of 1919 and newspapers feature alarming headlines about incidences of mad cow disease, infectious disease will be a critical area of concern and scientific study in the twenty-first century. Infectious Disease collects thirty of the most exciting, innovative, and significant articles on communicable illness published in the pages of Scientific American magazine since 1993. With sections devoted to viral infections,... |
 |
Infectious Disease Epidemiology: Theory And Practice by Kenrad E., M.D. Nelson (Author), Carolyn F. Masters, Ph.D. Williams (Author) This thorough revision contains new chapters on principles of immunology, measles and polio, meningococcal infections, including pneumococcal, and influenza infections. The chapter on emerging infections has been divided into one of mosquito borne infections and includes West Nile Virus, Rift V and Dengue as well as other arthropod borne infections. SARS and Monkey Poxare included in the new chapter. All other chapters have been updated. |
 |
Current Diagnosis & Treatment in Infectious Diseases by Walter Wilson (Author), Merle Sande (Author) Internationally renowned infectious disease experts offer guidance in recognizing, diagnosing, treating, and preventing one of the leading causes of death worldwide. Clinically focused and comprehensive, the book covers the essentials of diagnosis and syndromes in children and adults. Examines antimicrobial resistance and balances expert, practice-oriented coverage with just the right amount of microbiology concepts. |
| © 2010 BrightSurf.com |